Panel Discussion: Defining the Most Valuable Use Cases for mRNA-LNP Therapeutics: Prioritising Applications with the Greatest Clinical & Commercial Potential

• Identifying “sweet spots” for mRNA-LNP therapeutics based on dosing frequency, administration route & immune considerations
• Focusing development on validated applications: Cancer vaccines, infectious disease vaccines, protein replacement & in vivo CAR-T
• Learning from clinical setbacks to understand biological & commercial limitations of the platform

Speakers:

Christian Reinsch

Vice President Technology Profiling

BioNTech

Gilles Divita

Chief Executive Officer

Divincell

Ansgar Santel

Chief Executive Officer

Pantherna Therapeutics

Marco Stringhini

Principal Investigator, Project Leader

Almirall